Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | FCGR3B | O75015 | 1/20 | 0.36 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.36 |
| ▸ | FCGR2A | P12318 | 1/20 | 0.36 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623514 | 0.82 | MEN1 (0.41) | CDK1KDRCDC7ALKAGPAT2 | |
| SCHEMBL6811822 | 0.81 | ALDH1A1 (0.45) | KDRALKVSIRNR4A1 | |
| SCHEMBL2947601 | 0.80 | NR4A1 (0.56) | NR4A1 | |
| SCHEMBL1625171 | 0.79 | TXNRD1 (0.47) | — | |
| SCHEMBL2267169 | 0.78 | NPY5R (0.44) | KDR | |
| SCHEMBL1625229 | 0.74 | MEN1 (0.40) | CDK1KDRCDC7ALKPDPK1 | |
| SCHEMBL94186 | 0.74 | TNF (0.43) | MTNR1AMTNR1B | |
| SCHEMBL29634740 | 0.74 | TNF (0.43) | MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL7591939 | 0.73 | TNF (0.43) | MTNR1AMTNR1B | |
| SCHEMBL1625286 | 0.72 | CDK1 (0.42) | CDK1KDRCDC7ALKAGPAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928119-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7479564-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC. (JP) | 2009-01-20 | — | — | US | disclosed |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PFIZER INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070066618-A1 | Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases | PFIZER INC. | 2007-03-22 | — | — | US | disclosed |
| US-7148234-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7141580-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1666480-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. | PFIZER PHARMACEUTICALS INC. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1326864-B1 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMA (JP) | 2006-03-15 | — | — | EP | disclosed |
| EP-1499305-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | Pfizer Japan Inc. (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| WO-2003086371-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | CDK1 2572/4885KDR 4379/4885CDC7 4230/4885 |
| US-20070066618-A1 | Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases | PTGER4, PTGER1, IL6 | CDK1 4286/4885KDR 2614/4885CDC7 4334/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | CDK1 4286/4885KDR 2614/4885CDC7 4334/4885 |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | CDK1 2544/4885KDR 4402/4885CDC7 4199/4885 |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PTGS1, PTGS2, PTGES | CDK1 1388/4885KDR 3681/4885CDC7 4199/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | CDK1 2522/4885KDR 1763/4885CDC7 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.